Biotech company marketing Nyloxin, Pet Pain-Away, Equine Pain-Away as well as Luxury Feet, Nutra Pharma Corporation (OTCMKTS:NPHC) on July 26, 2021 announced filing a new provisional patent for protecting its IPR surrounding development of nerve agent counter measures.
Rik J Deitsch, Chief Executive Officer of Nutra Pharma, said that the firm had announced project back in 2018. Deitsch added that the company findings demonstrate that the company’s products may protect against the damage caused by nerve agents like sarin gas and VX.
Deitsch said that the company will be working with experts in the field to have products in testing soon and that it will be working with universities, government agencies as well as private collaborators for furthering research as well as potentially licensing the technology.
Nerve agents can disrupt transfer of messages to organs through the nerves, which results from over-stimulation of certain receptors on the surface of the neurons.
The company also provided updates on plans as well as progress on ameliorating transparency as compliance.
The CEO said that Nutra Pharma has been lagging in filing of its public company reports and financials. He added that the firm has filed six of its delinquent reports since February2021 as it believes it is in the best interest of the company. Nutra is expediting process and its auditors have added five staff members besides commencing concurrent reviews of the remaining reports.
The firm will also augment brand awareness, product messaging as well as online visibility.
